Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 13/20 | 0.80 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19046554 | 0.90 | CFTR (0.65) | CFTRMEN1KMT2APOLBMAPK1 | |
| SCHEMBL19032835 | 0.89 | CFTR (0.81) | CFTRMEN1KMT2AALOX5PTGS2 | |
| SCHEMBL19046548 | 0.89 | CFTR (0.85) | CFTRMEN1KMT2AMAPK1MAPT | |
| SCHEMBL19032095 | 0.89 | CFTR (1.00) | CFTR | |
| SCHEMBL29478065 | 0.89 | CFTR (1.00) | CFTR | |
| SCHEMBL19046220 | 0.89 | CFTR (0.80) | CFTRMEN1KMT2AALOX5PTGS2 | |
| SCHEMBL19032864 | 0.88 | CFTR (0.82) | CFTRMEN1KMT2APOLBMAPK1 | |
| SCHEMBL19032883 | 0.84 | CFTR (1.00) | CFTR | |
| SCHEMBL19032775 | 0.84 | CFTR (0.72) | CFTRMEN1KMT2APOLBMAPK1 | |
| SCHEMBL19032808 | 0.80 | CFTR (0.75) | CFTRMEN1KMT2AMAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503447-B2 | CFTR regulators and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-12-23 | — | — | US | disclosed |
| EP-4071140-B1 | CFTR REGULATORS AND METHODS OF USE THEREOF | UNIV CALIFORNIA (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-4071140-B1 | CFTR REGULATORS AND METHODS OF USE THEREOF | UNIV CALIFORNIA (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-4071140-A1 | CFTR REGULATORS AND METHODS OF USE THEREOF | The Regents of The University of California (US) | 2022-10-12 | — | — | EP | disclosed |
| EP-4071140-A1 | CFTR REGULATORS AND METHODS OF USE THEREOF | The Regents of The University of California (US) | 2022-10-12 | — | — | EP | disclosed |
| EP-3394046-B1 | CFTR REGULATORS AND METHODS OF USE THEREOF | UNIV CALIFORNIA (US) | 2022-03-09 | — | — | EP | disclosed |
| US-20210347742-A1 | CFTR REGULATORS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-11-11 | — | — | US | disclosed |
| US-11084795-B2 | CFTR regulators and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-08-10 | — | — | US | disclosed |
| CN-108699040-B | Modulators of CFTR and methods of use thereof | 加利福尼亚大学董事会 | 2021-08-10 | — | — | CN | disclosed |
| US-20190031622-A1 | CFTR REGULATORS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-01-31 | — | — | US | disclosed |
| EP-3394046-A1 | CFTR REGULATORS AND METHODS OF USE THEREOF | The Regents of the University of California, A California Corporation (US) | 2018-10-31 | — | — | EP | disclosed |
| WO-2017112950-A1 | CFTR REGULATORS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-06-29 | — | — | WO | disclosed |
| WO-2017112950-A1 | CFTR REGULATORS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031622-A1 | CFTR REGULATORS AND METHODS OF USE THEREOF | CFTR, SLC26A4, CLCN2 | CFTR 1/4885MEN1 4526/4885KMT2A 4498/4885 |
| US-20210347742-A1 | CFTR REGULATORS AND METHODS OF USE THEREOF | CFTR, SLC26A4, CLCN2 | CFTR 1/4885MEN1 4526/4885KMT2A 4498/4885 |
| US-11084795-B2 | CFTR regulators and methods of use thereof | CFTR, SLC26A4, CLCN2 | CFTR 1/4885MEN1 4526/4885KMT2A 4498/4885 |
| US-12503447-B2 | CFTR regulators and methods of use thereof | CFTR, SLC26A4, CLCN2 | CFTR 1/4885MEN1 4526/4885KMT2A 4498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.